Here are the 10-K annual reports from Bicara Therapeutics Inc. (BCAX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BCAX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAX filings page.
Bicara Therapeutics Inc. provides its annual business update focused on ficerafusp alfa, a bifunctional EGFR/TGF-β antibody for solid tumors. The company is running the global double-blind FORTIFI-HN01 Phase 2/3 pivotal trial in first-line HPV-negative head and neck squamous cell carcinoma, targeting substantial enrollment by the end of 2026 and an interim analysis in mid-2027.
Earlier Phase 1/1b data in 1L recurrent/metastatic HPV-negative head and neck cancer showed a confirmed overall response rate of 54% at the 1500mg weekly dose in combination with pembrolizumab, with a median overall survival of 21.3 months. Bicara is also exploring ficerafusp alfa in additional tumors, including colorectal, cutaneous squamous cell, and anal squamous cell carcinomas, and reports a generally manageable safety profile dominated by EGFR-related rash and low-grade mucosal bleeding events.